Cargando…
Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197
The p38 mitogen‐activated protein kinase (p38) is a key signaling pathway involved in regulation of inflammatory cytokines. Unexpectedly, several clinical studies using p38 inhibitors found no convincing clinical efficacy in the treatment of chronic inflammation. It was the objective of this study t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759708/ https://www.ncbi.nlm.nih.gov/pubmed/26904383 http://dx.doi.org/10.1002/psp4.12037 |
_version_ | 1782416770828599296 |
---|---|
author | De Buck, S Hueber, W Vitaliti, A Straube, F Emotte, C Bruin, G Woessner, R |
author_facet | De Buck, S Hueber, W Vitaliti, A Straube, F Emotte, C Bruin, G Woessner, R |
author_sort | De Buck, S |
collection | PubMed |
description | The p38 mitogen‐activated protein kinase (p38) is a key signaling pathway involved in regulation of inflammatory cytokines. Unexpectedly, several clinical studies using p38 inhibitors found no convincing clinical efficacy in the treatment of chronic inflammation. It was the objective of this study to characterize the population pharmacokinetics (PK) of BCT197 in healthy volunteers and to examine the relationship between BCT197 exposure and pharmacodynamics (PD) measured as inhibition of ex vivo lipopolysaccharide (LPS)‐induced tumor necrosis factor alpha (TNFα), a downstream marker of p38 activity. PK was characterized using a two‐compartment model with mixed‐order absorption and limited‐capacity tissue binding. The PK‐PD relationship revealed that suppression of TNFα was partly offset over time, despite continuous drug exposure. This may indicate a mechanism by which the inflammatory response acquires the ability to bypass p38. Simulations of posology dependence in drug effect suggest that an intermittent regimen may offer clinical benefit over continuous dosing and limit the impact of tolerance development. |
format | Online Article Text |
id | pubmed-4759708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47597082016-02-22 Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197 De Buck, S Hueber, W Vitaliti, A Straube, F Emotte, C Bruin, G Woessner, R CPT Pharmacometrics Syst Pharmacol Original Articles The p38 mitogen‐activated protein kinase (p38) is a key signaling pathway involved in regulation of inflammatory cytokines. Unexpectedly, several clinical studies using p38 inhibitors found no convincing clinical efficacy in the treatment of chronic inflammation. It was the objective of this study to characterize the population pharmacokinetics (PK) of BCT197 in healthy volunteers and to examine the relationship between BCT197 exposure and pharmacodynamics (PD) measured as inhibition of ex vivo lipopolysaccharide (LPS)‐induced tumor necrosis factor alpha (TNFα), a downstream marker of p38 activity. PK was characterized using a two‐compartment model with mixed‐order absorption and limited‐capacity tissue binding. The PK‐PD relationship revealed that suppression of TNFα was partly offset over time, despite continuous drug exposure. This may indicate a mechanism by which the inflammatory response acquires the ability to bypass p38. Simulations of posology dependence in drug effect suggest that an intermittent regimen may offer clinical benefit over continuous dosing and limit the impact of tolerance development. John Wiley and Sons Inc. 2015-11-09 2015-12 /pmc/articles/PMC4759708/ /pubmed/26904383 http://dx.doi.org/10.1002/psp4.12037 Text en © 2015 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles De Buck, S Hueber, W Vitaliti, A Straube, F Emotte, C Bruin, G Woessner, R Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197 |
title | Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197 |
title_full | Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197 |
title_fullStr | Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197 |
title_full_unstemmed | Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197 |
title_short | Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197 |
title_sort | population pk‐pd model for tolerance evaluation to the p38 map kinase inhibitor bct197 |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759708/ https://www.ncbi.nlm.nih.gov/pubmed/26904383 http://dx.doi.org/10.1002/psp4.12037 |
work_keys_str_mv | AT debucks populationpkpdmodelfortoleranceevaluationtothep38mapkinaseinhibitorbct197 AT hueberw populationpkpdmodelfortoleranceevaluationtothep38mapkinaseinhibitorbct197 AT vitalitia populationpkpdmodelfortoleranceevaluationtothep38mapkinaseinhibitorbct197 AT straubef populationpkpdmodelfortoleranceevaluationtothep38mapkinaseinhibitorbct197 AT emottec populationpkpdmodelfortoleranceevaluationtothep38mapkinaseinhibitorbct197 AT bruing populationpkpdmodelfortoleranceevaluationtothep38mapkinaseinhibitorbct197 AT woessnerr populationpkpdmodelfortoleranceevaluationtothep38mapkinaseinhibitorbct197 |